Abstract
No public abstract is available from the verified source records.
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment
10.1093/eurheartj/ehq426 · 2011
A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation
10.1016/j.jacc.2013.02.092 · 2013
The pathophysiology of heart failure with preserved ejection fraction
10.1038/nrcardio.2014.83 · 2014
Cell therapy for cardiac repair—lessons from clinical trials
10.1038/nrcardio.2014.9 · 2014
Breakthroughs in cell therapy for heart disease: focus on cardiosphere-derived cells
10.1016/j.mayocp.2014.02.014 · 2014
Cardiosphere-derived cells reverse heart failure with preserved ejection fraction in rats by decreasing fibrosis and inflammation
2016
Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance
10.1152/ajpheart.01017.2005 · 2006
Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction
10.1016/j.jacc.2009.05.013 · 2009
The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion
10.1016/j.jacc.2009.03.037 · 2009
Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction
10.1016/j.jacc.2010.03.077 · 2010
Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone
10.1161/circulationaha.115.015884 · 2015
Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction
10.1161/circulationaha.106.632745 · 2006
Right heart dysfunction in heart failure with preserved ejection fraction
10.1093/eurheartj/ehu193 · 2014
Right ventricular function in heart failure with preserved ejection fraction: a community-based study
10.1161/circulationaha.113.008461 · 2014
Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction
10.1161/circheartfailure.114.002114 · 2015
Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction
10.1016/j.jacc.2011.02.055 · 2011
Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction
10.1161/circheartfailure.114.001825 · 2015
Phenomapping for novel classification of heart failure with preserved ejection fraction
10.1161/circulationaha.114.010637 · 2015
Matchmaking for the optimization of heart failure with preserved ejection fraction clinical trials: no laughing matter
10.1016/j.jacc.2013.07.010 · 2013
Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction
10.1161/circulationaha.114.009625 · 2015
No additional external references are available.